Liver Transplantation and Hepatic Resection can Achieve Cure for Hepatocellular Carcinoma

医学 肝细胞癌 肝移植 人口 统计显著性 米兰标准 内科学 移植 外科 胃肠病学 肿瘤科 环境卫生
作者
Antonio Daniele Pinna,Tian Yang,Vincenzo Mazzaferro,Luciano De Carlis,Jian Zhou,Sasan Roayaie,Feng Shen,Carlo Sposito,Matteo Cescon,Stefano Di Sandro,Yifeng He,Philip J. Johnson,Alessandro Cucchetti
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
卷期号:268 (5): 868-875 被引量:219
标识
DOI:10.1097/sla.0000000000002889
摘要

OBJECTIVE: The aim of this study was to estimate probabilities of achieving the statistical cure from hepatocellular carcinoma (HCC) with hepatic resection (HR) and liver transplantation (LT). BACKGROUND: Statistical cure occurs when the mortality of a specific population returns to values of that of general population. Resection and transplantation are considered potentially curative therapies for HCC, but their effect on the residual entire life-expectancy has never been investigated. METHODS: Data from 3286 HCC patients treated with LT (n = 1218) or HR (n = 2068) were used to estimate statistical cure. Disease-free survival (DFS) was the primary survival measure to estimate cure fractions through a nonmixture model. Overall survival (OS) was a secondary measure. In both, patients were matched with general population by age, sex, year, and race/ethnicity. Cure variations after LT were also adjusted for different waiting-list drop-outs. RESULTS: Considering DFS, the cure fraction after LT was 74.1% and after HR was 24.1% (effect size >0.8). LT outperformed HR within all transplant criteria considered (effect size >0.8), especially for multiple tumors (>0.9) and even in presence of a drop-out up to 20% (>0.5). Considering OS, the cure fraction after LT marginally increased to 75.8%, and after that HR increased to 40.5%. The effect size of LT over HR in terms of cure decreased for oligonodular tumors (<0.5), became small for drop-out up to ∼20% (<0.2), and negligible for single tumors <5 cm (∼0.1). CONCLUSION: As other malignancies, statistical cure can occur for HCC, primarily with LT and secondarily with HR, depending on waiting-list capabilities and efficacy of tumor recurrence therapies after resection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Zyj发布了新的文献求助30
1秒前
思源应助HMS_Illustrious采纳,获得10
1秒前
哈哈发布了新的文献求助10
1秒前
BIGDUCK发布了新的文献求助10
1秒前
搜集达人应助zzZ5采纳,获得10
2秒前
CipherSage应助liqingsong采纳,获得10
2秒前
2秒前
雷凯洲发布了新的文献求助10
2秒前
SciGPT应助富贵采纳,获得10
3秒前
今后应助富贵采纳,获得10
3秒前
Copyright应助富贵采纳,获得10
3秒前
Jasper应助富贵采纳,获得10
3秒前
不读庚黄应助富贵采纳,获得10
4秒前
zz发布了新的文献求助10
4秒前
无花果应助富贵采纳,获得10
4秒前
情怀应助富贵采纳,获得10
4秒前
4秒前
FashionBoy应助富贵采纳,获得10
4秒前
香蕉觅云应助富贵采纳,获得10
4秒前
FashionBoy应助富贵采纳,获得10
4秒前
5秒前
888发布了新的文献求助10
5秒前
6秒前
认真的裙子完成签到,获得积分10
6秒前
热情的戾发布了新的文献求助10
9秒前
天乐69完成签到,获得积分10
10秒前
得鹿梦鱼发布了新的文献求助10
10秒前
10秒前
RoseTaurus发布了新的文献求助10
10秒前
10秒前
wanci应助富贵采纳,获得10
11秒前
Hello应助富贵采纳,获得10
11秒前
不读庚黄应助富贵采纳,获得10
11秒前
Jasper应助九三采纳,获得10
11秒前
11秒前
彭于晏应助富贵采纳,获得10
11秒前
BIGDUCK完成签到,获得积分10
11秒前
科研通AI2S应助富贵采纳,获得10
11秒前
今后应助富贵采纳,获得30
12秒前
搜集达人应助富贵采纳,获得10
12秒前
高分求助中
Principles of Economics, 11th Edition 10000
Prescott's Microbiology: 2026 Release ISE 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Environmental Leverage in Times of Climate Crisis: Product Standards, Carbon Border Measures and Preferential Trade Agreements 1000
Interactions of Vowel Quality and Prosody in East Slavic 1000
Erwählung und Berufung bei Paulus: Bedeutung, Entwicklung und Funktion einer Vorstellung in ihrem frühjüdischen und griechisch-römischen Kontext 850
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7193131
求助须知:如何正确求助?哪些是违规求助? 8829408
关于积分的说明 18641822
捐赠科研通 6829144
什么是DOI,文献DOI怎么找? 3175986
关于科研通互助平台的介绍 2328143
邀请新用户注册赠送积分活动 2150487